Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four.
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
Bone Biologics Corporation (
NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.
